Resumen de acción ATHE Alterity Therapeutics Limited se dedica a la investigación y desarrollo de fármacos terapéuticos para tratar la enfermedad de Alzheimer, la enfermedad de Huntington, la enfermedad de Parkinson y otros trastornos neurológicos en Australia. Saber más
Análisis de riesgos + 2 riesgos adicionales
Ver todos los controles de riesgos {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Alterity Therapeutics Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Alterity Therapeutics Precios históricos de las acciones Precio actual de la acción AU$4.34 Máximo en las últimas 52 semanas AU$5.87 Mínimo de 52 semanas AU$1.00 Beta 0.66 Cambio en 1 mes 29.94% Variación en 3 meses 267.80% Cambio de 1 año 112.75% Variación en 3 años -52.52% Variación en 5 años -36.49% Variación desde la OPV -99.36%
Noticias y actualizaciones recientes Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million. Feb 11
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million. Feb 04
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy Jan 30
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy Dec 04
Alterity Therapeutics Limited Announces Management Changes Nov 20
Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium Nov 12 Ver más actualizaciones Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million. Feb 11
Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million. Feb 04
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy Jan 30
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy Dec 04
Alterity Therapeutics Limited Announces Management Changes Nov 20
Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium Nov 12
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 Nov 06
Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024 Oct 23
Alterity Therapeutics Limited Announces Chief Financial Officer Changes Sep 30 Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.
Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy Jul 17
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review May 09
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases Apr 30 Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million. Feb 16
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review Feb 06 Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million. Jan 08
Alterity Therapeutics Limited Announces CFO Changes Dec 21
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease Dec 04
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy Nov 29
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy Nov 28
Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million. Nov 24 Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy Nov 10
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy Nov 09
Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023 Oct 31
Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's Aug 24
Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study Jul 27
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder May 31
Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy May 11
Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria Feb 16
Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease Jan 31
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy Jan 25
Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy Jan 09
Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office Dec 29
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting Oct 27 Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders Sep 26
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy Sep 20
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe Aug 25
Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK Aug 25
Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy Jul 06
Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy Jul 06
Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy Jun 23
Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial Jun 02
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom Apr 27
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting Apr 07
Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease Jan 30
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S Jan 07
Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial Dec 15
Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study Sep 21
Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology Sep 16
United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's Aug 06
Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective Jul 15
Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding Jul 03
Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's Jul 02
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial Jun 23
Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021 Feb 19
Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO Jan 08
Alterity Therapeutics names Dr. David Stamler as CEO Jan 07
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics Dec 21
Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases Nov 18
Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders Nov 16
Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study Oct 28
Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding Oct 16
Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt Sep 12
Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020 Sep 09 Rentabilidad de los accionistas ATHE US Biotechs Mercado US 7D -3.8% -4.2% 0.2% 1Y 112.7% -3.0% 23.1%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: ATHE superó a la industria US Biotechs, que obtuvo un rendimiento del -3% el año pasado.
Rentabilidad vs. Mercado: ATHE superó al mercado US, que obtuvo un rendimiento del 23.1% el año pasado.
Volatilidad de los precios Is ATHE's price volatile compared to industry and market? ATHE volatility ATHE Average Weekly Movement 24.7% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Precio estable de las acciones: El precio de las acciones de ATHE ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ATHE ha aumentado de 16% a 25% en el último año.
Acerca de la empresa Alterity Therapeutics Limited se dedica a la investigación y desarrollo de fármacos terapéuticos para tratar la enfermedad de Alzheimer, la enfermedad de Huntington, la enfermedad de Parkinson y otros trastornos neurológicos en Australia. El principal candidato a fármaco de la empresa es el ATH434, una pequeña molécula candidata a fármaco que ha completado la Fase I de ensayos clínicos para el tratamiento de la enfermedad de Parkinson. También está desarrollando el ATH434-201, que se encuentra en fase II de ensayo clínico para tratar la atrofia multisistémica en fase inicial; el ATH434-202, que se encuentra en fase II de ensayo clínico para tratar la atrofia multisistémica; y el PBT2, que ha completado la fase 2a de ensayo clínico para tratar la enfermedad de Alzheimer.
Mostrar más Resumen de fundamentos de Alterity Therapeutics Limited ¿Cómo se comparan los beneficios e ingresos de Alterity Therapeutics con su capitalización de mercado? Estadísticas fundamentales de ATHE Capitalización bursátil US$36.86m Beneficios(TTM ) -US$12.04m Ingresos (TTM ) US$2.53m
14.6x Ratio precio-ventas (PS)
-3.1x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de ATHE Ingresos AU$4.02m Coste de los ingresos AU$214.30k Beneficio bruto AU$3.80m Otros gastos AU$22.93m Beneficios -AU$19.12m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.0036 Margen bruto 94.67% Margen de beneficio neto -475.79% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado ATHE a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/02/11 10:00 Precio de las acciones al final del día 2025/02/11 00:00 Beneficios 2024/06/30 Ingresos anuales 2024/06/30
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas Alterity Therapeutics Limited está cubierta por 10 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Robert Wasserman Benchmark Company George Zavoico B. Riley Securities, Inc. Vernon Bernardino FBR Capital Markets & Co.
Mostrar 7 más analistas 
